Loading
MK-1045 is an experimental investigational agent whose form is not stated in the registry from Merck Sharp & Dohme in phase 3 trials for acute lymphoblastic leukaemia, follicular lymphoma and hodgkin lymphoma, aimed at CD19.
MK-1045 (CN-201, CN201) is an investigational agent whose form is not stated in the registry developed by Merck Sharp & Dohme and MSD R&D (China). Its target is CD19 (the sponsor names CD19). The sponsor states: MK-1045 is described as a novel immunotherapy, given intravenously, being compared with blinatumomab in relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07570173 (A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukaemia (MK-1045-005)) and NCT07634471 (A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)), in acute lymphoblastic leukaemia, follicular lymphoma, hodgkin lymphoma and diffuse large B-cell lymphoma. The largest, NCT07634471, plans to enrol 960 participants with primary completion expected 2032-07-23. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
MK-1045 is described as a novel immunotherapy, given intravenously, being compared with blinatumomab in relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia. Connects to CD19.
1.One arm of MK-1045 binds CD19 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MK-1045" OR ABSTRACT:"MK-1045" OR TITLE:"CN-201" OR ABSTRACT:"CN-201" OR TITLE:"CN201" OR ABSTRACT:"CN201") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MK-1045, not a curated reading list.
Shares CD19, Follicular lymphoma, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Follicular lymphoma, Hodgkin lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Hodgkin lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Follicular lymphoma, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19, Hodgkin lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.